No Difference in Adverse Events Between Delafloxacin or Vancomycin/Aztreonam in ABSSSI
The most common adverse events were gastrointestinal in both treatment groups. Photo Credit: Melinta Therapeutics, Inc.
|This article is part of Infectious Disease Advisor's coverage of IDWeek 2017™, taking place in San Diego, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2017.|
|Visit Infectious Disease Advisor's conference section for continuous coverage live from IDWeek 2017.|
Corey GR, Hooper D, Lodise Jr TP, Tseng C, Cammarata SK. Comparison of safety profile of delafloxacin (DLX) versus vancomycin/aztreonam (VAN/AZ) in thetreatment of patients (pts) with acute bacterial skin and skin structure infections (ABSSSI): integrated safety findings from two phase III studies. Presented at: IDWeek 2017; October 4-8, 2017; San Diego, California; Poster 1858.